Mirae Asset Global Investments
ACAD icon

Mirae Asset Global Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Mirae Asset Global Investments’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$194K Sell
7,658
-1,235
-14% -$27.2K ﹤0.01% 1123
2026
Q1 		$198K Buy
8,893
+672
+8% +$16.1K ﹤0.01% 1073
2025
Q4 		$220K Buy
8,221
+1,699
+26% +$40.6K ﹤0.01% 1131
2025
Q3 		$139K Buy
6,522
+57
+0.9% +$1.35K ﹤0.01% 1164
2025
Q2 		$139K Buy
6,465
+884
+16% +$16.4K ﹤0.01% 1094
2025
Q1 		$95.3K Buy
5,581
+36
+0.6% +$654 ﹤0.01% 1135
2024
Q4 		$94K Sell
5,545
-454
-8% -$7.33K ﹤0.01% 1160
2024
Q3 		$94.1K Buy
5,999
+1,066
+22% +$17.8K ﹤0.01% 1191
2024
Q2 		$80.8K Sell
4,933
-71,859
-94% -$1.16M ﹤0.01% 1169
2024
Q1 		$1.42M Sell
76,792
-8,988
-10% -$223K ﹤0.01% 1358
2023
Q4 		$2.69M Buy
85,780
+4,442
+5% +$106K 0.01% 1129
2023
Q3 		$1.7M Buy
81,338
+6,519
+9% +$177K ﹤0.01% 1250
2023
Q2 		$1.79M Sell
74,819
-1,854
-2% -$41.2K ﹤0.01% 1268
2023
Q1 		$1.44M Buy
76,673
+15,920
+26% +$303K ﹤0.01% 1356
2022
Q4 		$967K Buy
60,753
+844
+1% +$13.2K ﹤0.01% 1517
2022
Q3 		$980K Buy
59,909
+14,032
+31% +$227K ﹤0.01% 1493
2022
Q2 		$646K Buy
45,877
+33,924
+284% +$633K ﹤0.01% 1627
2022
Q1 		$289K Sell
11,953
-476
-4% -$11.5K ﹤0.01% 1515
2021
Q4 		$290K Buy
12,429
+139
+1% +$2.8K ﹤0.01% 1500
2021
Q3 		$204K Buy
12,290
+1,750
+17% +$33.7K ﹤0.01% 1687
2021
Q2 		$258K Buy
+10,540
New +$238K ﹤0.01% 1606
2021
Q1 		– Sell
-8,418
Closed -$450K – 1524
2020
Q4 		$450K Buy
8,418
+332
+4% +$16.5K ﹤0.01% 1346
2020
Q3 		$333K Buy
8,086
+808
+11% +$34.9K ﹤0.01% 1315
2020
Q2 		$352K Buy
+7,278
New +$349K ﹤0.01% 1267

Other funds holding ACAD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return

Mirae Asset Global Investments's ACAD Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Acadia Pharmaceuticals (ACAD) stake by 14% in Q2 2026, selling an estimated $27.2K and leaving 7,658 shares worth $194K. The position accounts for ﹤0.01% of the portfolio, ranked #1123.

Mirae Asset Global Investments first reported a position in ACAD in Q2 2020 and has held it in 24 quarters since. The position peaked at $2.69M in Q4 2023. 140 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Mirae Asset Global Investments held 7,658 shares of Acadia Pharmaceuticals worth $194K as of Q2 2026.
  • Mirae Asset Global Investments sold 1,235 Acadia Pharmaceuticals shares in Q2 2026, an estimated $27.2K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1123 holding.
  • Mirae Asset Global Investments first reported a position in Acadia Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • Mirae Asset Global Investments's Acadia Pharmaceuticals position peaked at $2.69M in Q4 2023.
  • 140 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.